Context Therapeutics Inc banner

Context Therapeutics Inc
NASDAQ:CNTX

Watchlist Manager
Context Therapeutics Inc Logo
Context Therapeutics Inc
NASDAQ:CNTX
Watchlist
Price: 2.92 USD 0.69% Market Closed
Market Cap: $268.3m

Relative Value

CNTX doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CNTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CNTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

CNTX Competitors Multiples
Context Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Context Therapeutics Inc
NASDAQ:CNTX
268.3m USD 0 -10.3 -6.3 -6.3
US
Eli Lilly and Co
NYSE:LLY
946.1B USD 14.5 45.8 30.9 33
US
Johnson & Johnson
NYSE:JNJ
586.8B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
267.4B CHF 4.3 20.4 12 13.5
UK
AstraZeneca PLC
LSE:AZN
226.4B GBP 5.1 29.6 16.4 23.1
CH
Novartis AG
SIX:NOVN
234.9B CHF 5.3 21.4 13.2 17
US
Merck & Co Inc
NYSE:MRK
289.8B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
154.4B USD 2.5 19.9 7.7 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
121B USD 2.5 17.2 7.2 8.9
P/E Multiple
Earnings Growth PEG
US
Context Therapeutics Inc
NASDAQ:CNTX
Average P/E: 22.5
Negative Multiple: -10.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.8
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
20.4
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.6
26%
1.1
CH
Novartis AG
SIX:NOVN
21.4
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
19.9
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Context Therapeutics Inc
NASDAQ:CNTX
Average EV/EBITDA: 46.5
Negative Multiple: -6.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.9
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
12
6%
2
UK
AstraZeneca PLC
LSE:AZN
16.4
13%
1.3
CH
Novartis AG
SIX:NOVN
13.2
5%
2.6
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Context Therapeutics Inc
NASDAQ:CNTX
Average EV/EBIT: 101.1
Negative Multiple: -6.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.7
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
23.1
21%
1.1
CH
Novartis AG
SIX:NOVN
17
9%
1.9
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
3%
3.1
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett